<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel diseases</z:e> (IBD) are <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> or <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Mainstays of drug treatments for IBD include aminosalicylates, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> such as <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and cyclosporin </plain></SENT>
<SENT sid="2" pm="."><plain>Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes </plain></SENT>
<SENT sid="3" pm="."><plain>New therapies are classified as: (1) Anti-TNFalpha antibodies; (2) Recombinant cytokines; (3) Selective <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatments have the potential to provide more effective and safe treatment for IBD </plain></SENT>
</text></document>